Ritedose Pharmaceuticals Launches <em>Cromolyn Sodium Inhalation Solution, USP (20 mg/2 ml)</em>
COLUMBIA, S.C. (August 24, 2023) – Ritedose, a pharmaceutical manufacturer located in South Carolina, launched a new sterile unit dose generic product, Cromolyn Sodium Inhalation Solution, USP (20 mg/2 ml). The single-dose vial product joins a range of other inhalation solutions produced by Ritedose Pharmaceuticals and is available in cartons
Novo Holdings to acquire Ritedose: <br><em>Novo Holdings A/S (“Novo Holdings”) today announced that it has agreed to acquire Ritedose from AGIC Capital and Humanwell.</em>
COPENHAGEN, Denmark, Jan. 4, 2022 /PRNewswire/ – Founded in 1995 and headquartered in Columbia, S.C., The Ritedose Corporation (“Ritedose”) is a leading sterile pharmaceutical manufacturer, specialising in the use of blow-fill-seal (BFS) technology. Ritedose provides outsourced development and manufacturing of ophthalmology drugs, respiratory drugs, and vaccines.
Recent Comments